Muriel Chen

In a report issued Wednesday, Credit Suisse analysts Vamil Divan and Muriel Chen assumed coverage of Portola Pharmaceuticals Inc (NASDAQ: PTLA) with an Outperform rating and $51 target price, on the back of an appealing emerging cardiovascular franchise. The analysts see the company as a high-...